Precision Biosciences Inc 8-K Filing

FAQ

Key Financial Figures

• $0.000005 — ich registered Common Stock, par value $0.000005 per share DTIL The Nasdaq Capital Marke
• $6.14 — of Common Stock at a combined price of $6.14 and, in lieu of common stock to certain
• $6 — of Common Stock at a combined price of $6.139995, which represents the per share
• $7.25 — five-year term and an exercise price of $7.25 per share. The Company estimates the ne
• $70.0 m — from the offering will be approximately $70.0 million, after deducting underwriting dis

Filing Documents

• dtil-20251110.htm (8-K) — 39KB
• a11projectpapayaii-underwr.htm (EX-1.,1) — 233KB
• a41projectpapayaii-formofc.htm (EX-4.1) — 128KB
• a42projectpapayaii-formofp.htm (EX-4.2) — 132KB
• a51projectpapayaii-ex51opi.htm (EX-5.1) — 20KB
• a20251110projectpapayaii-p.htm (EX-99.,1) — 12KB
• latham.jpg (GRAPHIC) — 76KB
• 0001628280-25-051382.txt ( ) — 896KB
• dtil-20251110.xsd (EX-101.SCH) — 2KB
• dtil-20251110_lab.xml (EX-101.LAB) — 22KB
• dtil-20251110_pre.xml (EX-101.PRE) — 13KB
• dtil-20251110_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On November 10, 2025, Precision BioSciences, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Guggenheim Securities, LLC (the "Underwriter"), in connection with the offering (the "Offering"), issuance and sale by the Company of 10,815,000 shares of its common stock, $0.000005 par value per share (the "Common Stock") and accompanying one-half warrants to purchase up to 5,407,500 shares of Common Stock at a combined price of $6.14 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,400,000 shares of its Common Stock and accompanying one-half warrants to purchase up to 700,000 shares of Common Stock at a combined price of $6.139995, which represents the per share offering price for the shares of Common Stock less the $0.000005 per share exercise price for each pre-funded warrant. Each whole warrant has a five-year term and an exercise price of $7.25 per share. The Company estimates the net proceeds from the offering will be approximately $70.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company and excluding any proceeds the Company may receive upon exercise of the warrants or pre-funded warrants being sold in the Offering. The Company intends to use the net proceeds of the Offering to fund ongoing and planned research and development, and for working capital and other general corporate purposes. The shares of Common Stock, warrants and pre-funded warrants are being sold pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-272540). A prospectus supplement relating to the offer and sale of the Common Stock and warrants has been filed with the Securities and Exchange Commission. The closing of the Offering is expected to occur on November 12, 2025, subject to customary closing conditions. The warrants have an exercise price of $7.25 per share, are immediately

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits relating to Item 8.01 shall be deemed to be furnished, and not filed: Exhibit No. Description 1.1 Underwriting Agreement, dated November 10, 2025 between the Company and Guggenheim Securities, LLC 4.1 Form of Warrant 4.2 Form of Pre-Funded Warrant 5.1 Opinion of Latham & Watkins LLP 23.1 Consent of Latham & Watkins LLP (included in Exhibit 5.1) 99.1 Press release of Precision BioSciences, Inc. dated November 10, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRECISION BIOSCIENCES, INC. Date: November 12, 2025 By: /s/ John Alexander Kelly John Alexander Kelly Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR